News
3 Things You Should Expect in Gilead Sciences' Q3 Results
Things are looking up for Gilead Sciences (NASDAQ: GILD) for the first time in quite a while. Although the big biotech stock fell in the first half of 2017, its share price is up big since late....
3 Healthcare Stocks for Your Radar
The healthcare sector is one the most exciting and volatile industries out there, with clinical trial results and administrative changes having the potential to make or break so many companies.....
3 Arguments for and Against Legalizing Marijuana
There's arguably no industry in the U.S. that's growing at a faster, more consistent pace than legal marijuana. Marijuana Business Daily's latest report, "Marijuana Business Factbook 2017,"....
This Marijuana Stock Could Be the Biggest Comeback Story of 2018
Insys Therapeutics (NASDAQ: INSY) is one of the most hated biotech stocks on the market today. That's the case, at least, if you use short interest as a proxy for how much investors hate a given....
Should You Avoid Celgene Stock After Its Big Pipeline Setback?
Even some of the biggest and best have things go wrong every now and then. Celgene (NASDAQ: CELG) has been the best-performing biotech stock over the last five years among big biotechs with market....
5 Key Drugs Critical to Johnson & Johnson's Future
Johnson & Johnson (NYSE: JNJ) recently shared its third-quarter financial report card with investors, and by all measures, it deserves kudos. However, the stock market rewards investors based....
Legalizing Recreational Marijuana in Colorado Reversed a 14-Year Trend of Rising Opioid-Related Deaths
The marijuana industry is, for lack of a better pun, sprouting like a weed. According to cannabis research firm ArcView, the North American legal weed market grew by 34% in 2016 and is expected to....
Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies Inc.
Biotech investors are always looking for the next big thing. That's exactly what they found in Exelixis (NASDAQ: EXEL), which ranked as one of the top biotech stocks of 2016 (and 2015 also). But....
3 Stocks That Turned $3,000 Into $7,300 or More So Far in 2017
If you have just $3,000 to invest, that's a good foundation upon which to start building your portfolio. But resist the urge to bet it all on just one stock. Diversifying your holdings, even when....
3 Healthcare Stocks That Soared This Week: Are They Buys?
It's stunning just how much healthcare stocks can move in only a matter of five days. For three healthcare stocks, the past week was especially fantastic thanks to major catalysts.TransEnterix....
How Big of a Deal Is Celgene's Flop?
Celgene (NASDAQ: CELG) shuttered two GED-301 Crohn's disease trials this week after an interim look at data by independent monitors proved disappointing. The late-stage failure dings Celgene's....
Why uniQure N.V. Stock Is Hopping Today
Shares of the gene therapy company uniQure N.V. (NASDAQ: QURE) rose by as much as 27% in early-morning trading today on over 27 times the average volume. uniQure's stock is responding positively....
Why Celgene Corporation Dropped Today
Celgene (NASDAQ: CELG) is down 10.2% at 12:09 p.m. Friday after announcing yesterday after the market closed that it was stopping a clinical trial testing GED-0301 (mongersen) in Crohn's disease....
3 High-Yield Pharmaceutical Stocks
Pharmaceutical stocks are generally an outstanding place to look for sustainable sources of passive income. Even though most companies offer fairly modest yields due to the costly nature of....
Why Marijuana Stocks Won't Pay a Dividend, Even if They're Profitable
There aren't too many industries that can grow at 20%-plus a year over the next five years, but marijuana could be one of them. Cannabis research firm ArcView believes the legal North American pot....
Celgene Could Be the Best CAR-T Stock to Buy, Not Gilead Sciences
Gilead Sciences' (NASDAQ: GILD) recently approved Yescarta could be a billion-dollar blockbuster cancer-cell therapy, but the company could face stiff competition from Celgene (NASDAQ:....
Gilead Slaps Mega-Price on Its Newly Approved CAR-T
Gilead Sciences (NASDAQ: GILD) recently acquired clinical-stage CAR-T drugmaker Kite Pharma, for $11.9 billion and on Wednesday, the FDA helped validate the company's purchase price by approving....
Why Agenus Inc. Stock Slumped Today
Shares of the cancer immunotherapy and vaccine company Agenus (NASDAQ: AGEN) fell by as much as 16.7% on nearly five times the average volume today, before ultimately ending the day down by only....
Abbott Laboratories Q3 2017 Earnings Conference Call Transcript (ABT)
Abbott Laboratories (NYSE: ABT)Image source: The Motley Fool.Q3 2017 Earnings Conference CallOct. 18, 2017, 9:00 a.m. ET Continue readingSource: Fool.com
BOIRON : Activité du troisième trimestre 2017
ACTIVITÉ DU TROISIÈME TRIMESTRE 2017
(Données non auditées)
ACTIVITÉ CUMULÉE À FIN SEPTEMBRE 2017
en milliers d'euros
2016
2017
Var. taux courant 2017/2016
Var. taux constant....
BOIRON : Activity in the third quarter of 2017
ACTIVITY IN THE THIRD QUARTER OF 2017
(Unaudited data)
CUMULATIVE ACTIVITY AS OF THE END OF SEPTEMBER 2017
in thousands of euros
2016
2017
Variation
at current exchange....
Here's Why Corbus Pharmaceuticals Holdings Inc. Jumped Today
In response to upbeat results released from a phase 2 clinical trial, shares of Corbus Pharmaceuticals (NASDAQ: CRBP), a clinical-stage biotech focused on inflammatory and fibrotic diseases,....
3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax
At one point this year, Cara Therapeutics (NASDAQ: CARA) stock was up more than 175%. Most of those gains were given up, though. The stock is now up a little over 30% year to date. But that's....
3 Small-Cap Biotech Stocks That Could Be Big Winners in 2018
Small-cap biotech stocks, or companies with valuations ranging from $300 million to $2 billion, can generate truly astonishing returns on capital in exceptionally short periods of time. Several of....
3 High-Yield Stocks for Conservative Investors
Conservative equates to cautious. We're talking investing here, of course, and not politics. Conservative investors are by nature cautious. There's nothing wrong with that. After all, Warren....